DT-120 targets generalized anxiety disorder with optimized LSD pharmacotherapy designed to fit modern psychiatric practice and improve scalability

DT-120 is an LSD-based treatment candidate for generalized anxiety disorder that aims to close a major gap in care with a shorter, more practical psychedelic therapy model. The approach centers on optimizing LSD pharmacotherapy so it can fit more readily into contemporary psychiatric settings than longer, resource-intensive psychedelic treatment formats. Generalized anxiety disorder remains common, impairing, and often insufficiently treated by existing medications and psychotherapy alone. An optimized LSD intervention could matter if it preserves meaningful therapeutic benefit while reducing logistical barriers such as long session times, staffing demands, and limited clinic throughput. The clinical framing links psychedelic medicine to real-world implementation, not only symptom reduction. Scalability, feasibility, and integration into standard mental health care appear central to why DT-120 is being positioned as a differentiated option for anxiety treatment development.